Ann Hammarstrand has decided to leave his role as CFO for new challenges outside AroCell.
Ann Hammarstrand has decided to leave his role as CFO to look for new challenges outside of AroCell. «I want to thank Ann for her ambitious and accurate work for AroCell and wish her the best of luck in future challenges», says Johan von Heijne, acting CEO and member of the board of AroCell. The process to find a replacement is in full swing. Ann Hammarstrand ending as CFO during the hösten2018.
Arocell has during the year established, the number of commercial partners such as south Korean Green Cross Cell, and most recently successfully licensed out the technology to one of the world’s largest diagnostics company Roche Diagnostics.
«There is a significant potential AroCells technology and business relationships», says Claes Post, chairman of the board of AroCell AB «the Company now wants to accelerate the commercialization by deepening existing and establishing new partnerships. The company also intends to broaden the applications, then the tk1 analysis. The board intends to introduce a new, permanent direction in the autumn with the right profile to realize Arocells full potential,»continues Claes Mail.
For further information:
Claes Post, Chairman Of The Board
Telephone: 073-656 92 28
Johan von Heijne, Acting PRESIDENT
Telephone: 0705-95 15 10
This information is such information that AroCell AB (publ) is obliged to publish under the EU marknadsmissbruksförordning. The information was submitted, by Claes Posts in the government, for publication on 10 July. In 2018 there is a 08.00
Short of AroCell
AroCell AB (AROC) is a Swedish company that develops standardized modern blood tests to support the treatment, prognosis, and follow-up of cancer patients. AroCells technology is based on patented methods for measuring the protein Thymidine Kinase 1 (then the tk1) in the blood. TK 210(TM) ELISA test provides valuable information that will help clinicians to optimize treatment strategies and to forecast the risk of recurrence of cancer at the monitoring and follow-up of the patient. AroCell (AROC) is listed on Nasdaq First North with Redeye AB as Certified Adviser.
2018-07-10 Recruits new CFO
This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: AroCell AB via Globenewswire